Advicenne Publishes its 2019 Half-Year Financial Report

NÎMES, France--()--Regulatory News:

Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC - FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, today announces the publication of its 2019 half-year financial report.

This report is available in electronic version on the Company's website (www.advicenne.com) under the section ‘Investors’.

About Advicenne

Advicenne (Euronext - ADVIC) is dedicated to developing and commercializing innovative treatments for those suffering from rare kidney disease. Our lead drug candidate, is currently in late-stage clinical trials for two indications.

In 2017, ADV7103 was granted orphan drug designation by the European Commission in the treatment of distal renal tubular acidosis (dRTA), a rare kidney disorder that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood. ADV7103 is currently in Phase III clinical trials for this indication in Europe, the United States and Canada, and a marketing application for the drug candidate has been submitted for centralized European review.

While we prepare its European commercial launch for dRTA, we are simultaneously conducting trials for ADV7103 in the treatment of cystinuria, a genetic disease characterized by a buildup of the amino acid cystine in the kidneys and bladder. ADV7103’s Phase II/III European clinical trials for this second indication were recently expanded to Belgium.

At Advicenne, we are committed to innovating in the areas of formulation and dosage. Tasteless and easy to administer, our products are commercialized in small-size formats that offer flexible, personalized dosing – because path-breaking treatments for rare diseases should be available to patients of all ages.

Headquartered in Nîmes, France, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019.

www.advicenne.com

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Advicenne, which shall not be considered per se as historical facts. Such statements include projections and estimates, and the hypotheses on which these are based, as well as observations relating to operations, ongoing projects, objectives, the development of products and their future performance, and expectations regarding financial results.

In some cases, forward-looking statements can be identified by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets" or similar words. Although the management of Advicenne believes that these forward-looking statements are reasonably made, investors should be aware that they are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In particular, the expectations of Advicenne could be affected by, among other things, uncertainties involved in the placing on the market and commercialization of Advicenne products or any other risks and uncertainties developed or identified in any public documents filed by Advicenne with the French Financial Markets Authority (Autorité des marchés financiers (AMF)), including those listed in Chapter 4, “Risk Factors,” of its reference document, filed with the latter on December 3, 2018, under number R.18-073, and in Section 8 of its annual financial report published on April 30, 2019. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be “accurate, precise and fairly presented”), Advicenne disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Any information relating to the use of drug candidates contained in the present press release is based on the results of ongoing studies at the time of the release’s publication. A drug candidate is a product that has not yet received marketing authorization from a health agency.

Contacts

Advicenne
Luc-André Granier, Paul Michalet, Julie Rachline
E-mail: investors@advicenne.com
+33 (0)4 66 05 54 20

Financial Communications
NewCap
Emmanuel Huynh & Alexia Faure
E-mail: advicenne@newcap.eu
+33 (0)1 44 71 94 94

Press Relations
Alize RP
Caroline Carmagnol
E-mail: advicenne@alizerp.com
+33 (0)6 64 18 99 59

US Investor Relations
Rx Communications Group, LLC
Paula Schwartz
Email: pschwartz@rxir.com
+001 917-322-2216

Contacts

Advicenne
Luc-André Granier, Paul Michalet, Julie Rachline
E-mail: investors@advicenne.com
+33 (0)4 66 05 54 20

Financial Communications
NewCap
Emmanuel Huynh & Alexia Faure
E-mail: advicenne@newcap.eu
+33 (0)1 44 71 94 94

Press Relations
Alize RP
Caroline Carmagnol
E-mail: advicenne@alizerp.com
+33 (0)6 64 18 99 59

US Investor Relations
Rx Communications Group, LLC
Paula Schwartz
Email: pschwartz@rxir.com
+001 917-322-2216